30th week of 2011 patent applcation highlights part 34 |
Patent application number | Title | Published |
20110182845 | Odor Inhibiting Water-Absorbing Composites - The present invention relates to a process for producing odor-inhibiting water-absorbing composites comprising water-absorbing polymer particles and fibers, wherein the fibers are premixed with at least one metal peroxide, metal hyperoxide or metal ozonide. | 2011-07-28 |
20110182846 | Surface Treating Agent, Surface-Treated Powder, And Cosmetic - The present invention provides a surface treating agent that can improve texture in use and impart excellent water resistance and sebum resistance. A surface treating agent comprising an organosiloxane derivative having a divalent or trivalent metal salt of a terminal carboxyl group, represented by the following formula (1) or (3). | 2011-07-28 |
20110182847 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS - Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/r TLR agonist). | 2011-07-28 |
20110182848 | GRANULOCYTE COLONY STIMULATING FACTOR - We disclose granulocyte colony stimulating factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said proteins. | 2011-07-28 |
20110182849 | COMPOSITIONS AND METHODS FOR TREATING AN INTERVERTEBRAL DISC USING BULKING AGENTS OR SEALING AGENTS - Effective compositions and methods for treating an intervertebral disc are provided. The compositions and methods comprise a bulking agent or sealing agent, the bulking agent or sealing agent adapted to be administered at or within the intervertebral disc, the bulking or sealing agent having a drug depot comprising an effective amount of a therapeutic agent disposed therein, wherein the drug depot is capable of releasing an effective amount of the therapeutic agent over a period of at least one day. | 2011-07-28 |
20110182850 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 2011-07-28 |
20110182851 | OXIDIZED LDL SPECIFIC ANTIBODY-FUSION AND CONJUGATED PROTEINS - The present invention relates to complete oxidized LDL specific IgG fused or conjugated with at least one of the proteins of the group IL-10, TIMPs, and TGFβs to be used in a medicine, the use thereof for treatment of atherosclerosis and prevention of clinical events in patients with atherosclerosis, pharmaceutical compositions containing the same, as well as method for treatment of atherosclerosis and prevention of clinical events in patients with atherosclerosis. | 2011-07-28 |
20110182852 | IL28 AND IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME - IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections. | 2011-07-28 |
20110182853 | PLATELET DERIVED GROWTH FACTOR (PDGF)-DERIVED NEUROSPHERES DEFINE A NOVEL CLASS OF PROGENITOR CELLS - The present invention is related to the discovery of a novel class of neural progenitor cells, which proliferate in response to platelet derived growth factor (PDGF) and differentiate into neurons and oligodendrocytes but not astrocytes. Progeny of the progenitor cells can be obtained by culturing brain tissue in PDGF without serum, epidermal growth factor (EGF), fibroblast growth factor 2, or transforming growth factor alpha. Upon subculturing into EGF-containing media, these progeny cells can proliferate and form neurospheres, whereas PDGF has no such effect. | 2011-07-28 |
20110182854 | HCV PROTEASE INHIBITORS - Novel compounds that are potent inhibitors of hepatitis C virus protease are provided. Pharmaceutical compositions containing one or more of these inhibitors, methods of preparing the inhibitors and methods of using the inhibitors to treat hepatitis C and related disorders also are provided. | 2011-07-28 |
20110182855 | CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION - Novel biologically active compounds of the general formula (I) in which one of X and X′ represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X′ represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X′ and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z | 2011-07-28 |
20110182856 | INHIBITORS OF SERINE PROTEASES - The present invention relates to compounds of formula (I): | 2011-07-28 |
20110182857 | Delivery of Drugs to Mucosal Surfaces - Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions. | 2011-07-28 |
20110182858 | SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS - The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin | 2011-07-28 |
20110182859 | Compositions and methods for therapeutic delivery with microorganisms - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that include modified microorganisms including at least one genetic element encoding at least one therapeutic agent or environmental treatment agent. | 2011-07-28 |
20110182860 | BIOCONTROL COMPOSITE MICROBIAL AGENT PSX COMBINATION FOR CONTROLLING SEVERAL SOIL-BORNE DISEASES AND ITS BACTERIOLOGICAL COMPOSITION - A composite biocontrol microbial agent PSX combination controls several soil-borne diseases. The PSX combination was composed of three biocontrol bacteria, which are shaking cultured in the PDA culture solution at 37° C., 180 rpm for 20 to 24 hours, then centrifugated at 4000 g for 10 min, taking the wet bacterium preserved fluid by the ratio of 1:40 to prepare the microbial agent, and then mixing at the ratio of 1:1:1, the total concentration of live bacteria in finished product being of 1×10 | 2011-07-28 |
20110182861 | COSMETIC USE OF MICROORGANISMS FOR THE TREATMENT OF OILY SKIN - The present invention relates to the cosmetic use of an effective amount of at least one probiotic microorganism and/or a fraction thereof and/or a metabolite thereof, as an agent for treating and/or preventing oily skin or skin with an oily tendency and the associated skin disorders. | 2011-07-28 |
20110182862 | ENDOPHYTIC FUNGUS AND USES THEREFOR - The present invention provides novel microorganisms, compositions and methods of use thereof, for treating, inhibiting or preventing the developing of a plant pathogenic disease and for killing or inhibiting growth of a variety of pests or pathogens. Provided are compositions comprising a novel endophytic fungal organism effective to inhibit the growth of or kill pests and pathogenic microbes, including | 2011-07-28 |
20110182863 | ANTI-BACTERIA COMPOSITIONS - The invention relates to anti-bacterial compositions comprising bacteriophage (phage) in sufficiently high concentrations to induce lysis from without in bacteria. Uses of such compositions are disclosed. Phase K and/or P68 are especially preferred. | 2011-07-28 |
20110182864 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES - The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula: | 2011-07-28 |
20110182865 | Method for Prophylaxis and Treatment of Equine Herpesvirus Type 1 Infections - Provided are compositions and methods for treatment and/or prophylaxis of EHV-I infections in horses. The compositions and methods effect treatment and/or prophylaxis of EHV-I infections through RNAi mediated inhibition of EHV-I gB and EHV-I Ori genes, which results in a reduction of the severity of neurological symptoms that are induced by EHV-I infection in horses, and/or a reduction in EHV-I viral shedding in the horses. Included are siRNAs or shRNAs that are designed to target EHV-I gB and EHV-I Ori helicase mRNAs. Also included are vectors encoding such shRNAs. | 2011-07-28 |
20110182866 | ISOLATION OF STEM CELL PRECURSORS AND EXPANSION IN NON-ADHERENT CONDITIONS - Stem cells and compositions thereof are isolated, cultured and expanded. Culture conditions and methods of culturing the isolated stem cells provide non-adherent stem cells which are prophylactically and therapeutically more effective in patients, diagnostics, screening assays and other stem cell uses. | 2011-07-28 |
20110182867 | MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES - The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies. | 2011-07-28 |
20110182868 | HUMAN LYSOSOMAL PROTEINS FROM PLANT CELL CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 2011-07-28 |
20110182869 | TREATMENT OF GUT MOTILITY DISORDERS - This invention relates to products comprising antibiotics or probiotics and the use thereof for the treatment of gut motility disorders such as irritable bowel syndrome (IBS). | 2011-07-28 |
20110182870 | GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MULTIPLE TUMOR ANTIGENS OR MULTIPLE VIRUSES - The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane. | 2011-07-28 |
20110182871 | NOVEL MICROORGANISM AND PLANT DISEASE CONTROL AGENT USING THE MICROORAGNISM - A novel microorganism which can be expected to have both a preventive effect and a therapeutic effect and may be applied to various phytopathogenic bacteria, and whose effects are not reduced even when used in combination with a chemical pesticide, and a plant disease control agent using the microorganism are provided. | 2011-07-28 |
20110182872 | METHODS OF ANALYSIS OF POLYMORPHISMS AND USES THEREOF - The present invention provides methods for the assessment of diseases that result from the combined or interactive effects of two or more genetic variants, and in particular for diagnosing risk of developing such diseases in subjects using an analysis of genetic polymorphisms. Methods for the derivation of a net score indicative of a subject's risk of developing a disease are provided. | 2011-07-28 |
20110182873 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising | 2011-07-28 |
20110182874 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms. | 2011-07-28 |
20110182875 | NOVEL CLASS OF THERAPEUTIC PROTEIN BASED MOLECULES - The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy. | 2011-07-28 |
20110182876 | Methods of Treatment with Elastase - The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation. | 2011-07-28 |
20110182877 | SUSTAINED DELIVERY OF COMPSTATIN ANALOGS FROM GELS - The present invention features the sustained delivery of compstatin analog and, optionally, an additional active agent, by release from a macroscopic, gel-like deposit formed by administering a liquid solution containing the compstatin analog to an extravascular location in the body of a mammalian subject such as the vitreous chamber. | 2011-07-28 |
20110182878 | Anti-Ricin Antibody - The subject of the present invention is an anti-ricin antibody and the use thereof for the treatment of an individual suffering from ricin poisoning. | 2011-07-28 |
20110182879 | NOVEL HUMAN TRANSFERASE FAMILY MEMBERS AND USES THEREOF - The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 46743, 27417, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 46743, 27417, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 46743, 27417, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 2011-07-28 |
20110182880 | Combination Therapies Against Cancer - Specific oligonucleotide sequences, when given subcutaneously and in particular when administered on a mucous membrane, e.g. intranasally, intravaginally, or rectally, have a profound effect on various human cancer forms as confirmed in vivo, in animal studies, and in vitro, in human PBMCs collected from blood from healthy subjects and from patients suffering from CLL. The compounds are also preferably used in combination with a cancer therapy chosen among radiation treatment, hormone treatment, surgical intervention, chemotherapy, immunological therapies, photodynamic therapy, laser therapy, hyperthermia, cryotherapy, angiogenesis inhibition, or a combination of any of these, and most preferably an immunological treatment comprising the administration of an antibody to the patient. | 2011-07-28 |
20110182881 | SIGNATURE AND DETERMINANTS ASSOCIATED WITH METASTASIS AND METHODS OF USE THEREOF - The present invention provides methods of detecting cancer using biomarkers. | 2011-07-28 |
20110182882 | Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof - The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride. | 2011-07-28 |
20110182883 | NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. | 2011-07-28 |
20110182884 | P-CADHERIN ANTIBODIES - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention. | 2011-07-28 |
20110182885 | FORMULATIONS AND TREATMENTS FOR WELL-BEING - A formulation for well-being in humans including: extracts from the herbal varieties, | 2011-07-28 |
20110182886 | COMPOSITIONS AND METHODS FOR INHIBITING TUMOR PROGRESSION - Compositions and methods are provided for the classification, diagnosis, treatment, and prevention of tumors characterized by loss of REST function, expression of β2, and/or activation of Notch. Further compositions and methods are provided for modulation of cellular processes such as EMT, cell migration, and apoptosis. | 2011-07-28 |
20110182887 | HUMANIZED ANTI-CD22 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE - The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework regions of the immunoglobulin light chain variable region (“VK”). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients. | 2011-07-28 |
20110182888 | Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator - Methods of treating patients with an HDAC inhibitor and a HER-2 inhibitor are provided herein. In some embodiments, a SERM is also administered. | 2011-07-28 |
20110182889 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NATURAL KILLER CELL RELATED DISEASES - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2011-07-28 |
20110182890 | ANTI-PLEIOTROPHIN ANTIBODIES AND METHODS OF USE THEREOF - The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein. | 2011-07-28 |
20110182891 | PHARMACEUTICAL DOSAGE FORM COMPRISING POLYMERIC CARRIER COMPOSITION - A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form. | 2011-07-28 |
20110182892 | Methods to identify responsive patients - The present invention provides methods and kits for improving the progression-free survival of a patient suffering from gastrointestinal cancer and for assessing the sensitivity or responsiveness of the patient to treatment comprising bevacizumab. | 2011-07-28 |
20110182893 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES - Passive immunotherapy methods for treating a patient having atherosclerosis. | 2011-07-28 |
20110182894 | Methods of treating diabetes using IL-1beta antibodies - An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides. | 2011-07-28 |
20110182895 | ANTIBODY VARIANTS - Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen. | 2011-07-28 |
20110182896 | CLOTTING FACTOR-Fc CHIMERIC PROTEINS TO TREAT HEMOPHILIA - The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region. | 2011-07-28 |
20110182897 | AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 2011-07-28 |
20110182898 | IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS - The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided. | 2011-07-28 |
20110182899 | ANTI-GLYCOPTROTEIN VI SCFV FRAGMENT FOR TREATMENT OF THROMBOSIS - The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly | 2011-07-28 |
20110182900 | COMPOSITIONS AND METHODS FOR TREATING COAGULATION RELATED DISORDERS - Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) to form a complex in which factor X or factor IX binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal. The invention has a wide spectrum of useful applications including treating sepsis, disorders related to sepsis, and inflammatory diseases such as arthritis. | 2011-07-28 |
20110182901 | FULL LENGTH LARGE T TUMOR ANTIGEN OF MERKEL CELL POLYOMAVIRUS AS A THERAPEUTIC TARGET IN MERKEL CELL CARCINOMA - The invention relates to a full length Large T tumor antigen of Merkel Cell Polyomavirus (MCV) as a therapeutic target in Merkel Cell Carcinoma (MCC). | 2011-07-28 |
20110182902 | Recombination Sequence (RS) Rearrangement Frequency as a Measure of Central B Cell Tolerance - The invention relates to methods and materials for diagnosing an autoimmune disease such as SLE, Type 1 diabetes, and the like. More particularly, the invention relates to methods and materials for assessing the frequency of recombination sequence (RS) rearrangement as a novel marker for an autoimmune disease. Such an assay can allow clinicians to diagnose an autoimmune disease based on the RS rearrangement frequency in an autoimmune patient as compared to an otherwise healthy control. In addition, the method includes identifying individuals who are at increased risk of developing autoimmunity. The method may also be helpful in directing the type of therapy and monitoring the effects of therapy in patients with autoimmune or non-autoimmune conditions. | 2011-07-28 |
20110182903 | NOVEL SOLUBLE CD83 POLYPEPTIDES, FORMULATIONS AND METHODS OF USE - Compositions and methods for treating or preventing unwanted immune responses are provided. The compositions relate to novel soluble CD83 (sCD83) polypeptides and nucleic acids encoding such polypeptides, improved (sCD83) formulations, and the use of such polypeptides and formulations in the treatment or prevention of allergy, autoimmune disease and transplant rejection. A sCD83 polypeptide is provided, comprising SEQ ID NO:7 or an amino acid sequence having at least 70% identity to SEQ ID NO:7; wherein one or more of amino acid residues 12, 20, 85 and 92 of SEQ ID NO:7 is an amino acid other than cysteine; and optionally, one or more of amino acid residues 1, 2, 3, 4 and 130 are absent. | 2011-07-28 |
20110182904 | ANTIBODIES TO BONE MORPHOGENIC PROTEINS AND RECEPTORS THEREFOR AND METHODS FOR THEIR USE - The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, which specifically bind to BMP2, BMP4, BMPR1A, BMPR1B, ACTR1, and/or BMPR2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Also provided are immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention and, optionally, one or more additional therapeutic. The invention also provides methods for treating diseases associated with abnormal bone formation and ossification mediated by BMP2, BMP4, BMPR1A, BMPR1B, ACTR15 and/or BMPR2. | 2011-07-28 |
20110182905 | MONOCLONAL ANTIBODIES THAT BIND TO HGM-CSF AND MEDICAL COMPOSITIONS COMPRISING SAME - Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF. | 2011-07-28 |
20110182906 | FULLY HUMAN ANTIBODY TO HUMAN TNF-ALPHA, MOLECULAR EVOLUTION AND USE THEREOF - The present invention relates to the discovery and improvement of proteins that can specifically bind with human TNFa (Tumor Necrosis Factor alpha), the proteins are full human anti human TNFa monoclonal antibodies derived from human B cells. This invention disclosed the anti human TNFa monoclonal antibodies, their amino acid sequence of light chain comprising SEQ ID NO:8, and that of heavy chain comprising SEQ ID NO:16 or SEQ ID NO:18. This invention disclosed the coding genes of these antibodies, their Fab molecules, and their potential application to treat clinically the diseases related to TNFa, such as inflammation diseases. | 2011-07-28 |
20110182907 | Anti-alpha-Enolase I Antibodies for Diagnosis and Treatment of alpha-Enolase I-Associated Diseases - The invention relates to antibodies against α-enolase I, their pharmaceutical compositions and diagnosis and treatment uses. Particularly, the invention provides polyclonal anti-α-enolase I antibodies and monoclonal single-chain variable fragment (scFv) anti-α-enolase antibodies, pharmaceutical compositions containing the same and their uses in uses in diagnosis and treatment of cancers, autoimmune disorders, ischemia and bacterial infection. | 2011-07-28 |
20110182908 | Diagnostics and Therapeutics for Macular Degeneration-Related Disorders - The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders. | 2011-07-28 |
20110182909 | Glufosfamide combination therapy - Glufosfamide administered in combination with other chemotherapeutic agents is useful in cancer treatment. | 2011-07-28 |
20110182910 | METHOD OF TREATING T CELL MEDIATED DISORDERS - A method of treating a T-cell mediated disorders in a tissue includes administering to the tissue of the subject a therapeutically effective amount of a complement antagonist that substantially reduces T-cell differentiation or t-cell inflammatory cytokine generation. | 2011-07-28 |
20110182911 | USE OF IMMOBILIZED ANTAGONISTS FOR ENHANCING GROWTH FACTOR CONTAINING BIOIMPLANT EFFECTIVENESS - A method of retaining growth factors on a substrate for release at a treatment region comprises immobilizing an antagonist of the growth factor on a substrate and binding of the growth factor to the antagonist. In one aspect, the substrate is provided on a bioimplant. The resulting bioimplant allows for activity of the growth factor to continue at the region of implantation. According to the method of the invention, exogenous growth factors can be used to stimulate the repair of various tissues and organs at the site requiring repair, and be protected from inactivation, sequestration or degradation. The invention also provides bioimplants and methods of delivering growth factors. | 2011-07-28 |
20110182912 | Agents and methods for denervation - Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue. | 2011-07-28 |
20110182913 | ANTI FGF23 ANTIBODY AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772). | 2011-07-28 |
20110182914 | METHODS AND COMPOSITIONS - The invention relates to methods for modulating granulocyte activation and migration, use of such methods in the treatment of diseases and compositions which may be employed in such methods and uses. In particular, the modulation of granulocyte activation/migration is achieved by increasing or decreasing the amount of lactoferrin in the vicinity of said granulocytes. | 2011-07-28 |
20110182915 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR OSTEOARTHRITIS - A method for treatment of disease classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis, or any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis, the method includes a step of administrating an agent containing an anti-Fas IgM antibody as an active ingredient. | 2011-07-28 |
20110182916 | Use of Agonists of Integrin Alpha 5 for Inducing the Osteogenic Differentiation of Mesenchymal Stem Cells - The invention relates to the use of agonists of integrin alpha for promoting osteoblast differentiation of mesenchymal stem cells. These agonists are useful in particular for enhancing osteogenesis in the treatments of diseases associated with bone loss or insufficient bone formation. | 2011-07-28 |
20110182917 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR GENERALIZED PAIN SYNDROME - Provided is a therapeutic or prophylactic agent for generalized pain syndrome, for which no cause and therapies have been established. A therapeutic or prophylactic agent for generalized pain syndrome containing an LPA1 antagonist or autotaxin-inhibiting substance as an active ingredient. The pharmaceutical is preferably administered to the central nervous system. The generalized pain syndrome is preferably fibromyalgia, chronic fatigue syndrome or hypersensitivity colitis. | 2011-07-28 |
20110182918 | Personalized drug treatment and smoking cessation kit and method - Described are smoking cessation devices and kits for determining an advantageous time for a subject to quit smoking, and/or for extending the duration of smoking abstinence, based on serum levels of anti-nicotine antibodies, and personalized drug treatment methods, including methods and kits for the treatment and prevention of drug addiction, drug use and drug abuse, which include determining the subject's pre-vaccine levels of antibodies specific for the drug hapten at issue. Related methods are also described. | 2011-07-28 |
20110182919 | Immunoglobulin Chimeric Monomer-Dimer Hybrids - The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention. | 2011-07-28 |
20110182920 | IDENTIFICATION OF A NOVEL CYSTEINE-RICH CELL PENETRATING PEPTIDE - The present invention relates to a nucleic acid molecule encoding a peptide capable of being internalized into a cell, wherein said nucleic acid molecule consists of (a) a nucleic acid molecule encoding a peptide having the amino acid sequence of SEQ ID NO: 2; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO: 1, wherein T is U if the nucleic acid molecule is RNA; or (d) a nucleic acid molecule encoding a peptide having at least 80% sequence identity with that of SEQ ID NO: 2, wherein at least at two positions selected from the group consisting of positions 1, 7 and 8 of SEQ ID NO: 2 a cysteine is present and wherein at least at four positions selected from the groups consisting of position 2, 4, 6, 9 or 10 of SEQ ID NO: 2 an arginine or a lysine is present. The present invention also relates to a peptide encoded by the nucleic acid of the invention, a fusion molecule comprising the peptide of the invention and a composition comprising the peptide or the fusion molecule of the invention. Furthermore, the present invention relates to a method of detecting the internalization behaviour of a fusion molecule of the invention, the composition of the invention for treating and/or preventing a condition selected from cancer, enzyme deficiency diseases, infarcts, cerebral ischemia, diabetes, inflammatory diseases, infections such as bacterial, viral or fungal infections, autoimmune diseases such as systemic lupus erythematodes (SLE) or rheumatoid arthritis, diseases with amyloid-like fibrils such as Alzheimer's disease (AD) and Parkinson's disease (PD) or certain forms of myopathy. | 2011-07-28 |
20110182921 | REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF - The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention. | 2011-07-28 |
20110182922 | PEPTIDES OF IL1 BETA AND TNF ALPHA AND METHOD OF TREATMENT USING SAME - The present invention relates to peptides derived from the proinflammatory cytokines, interleukin-1β (IL1β) and tumor necrosis factor α (TNFα), and their use in human or veterinary therapy, such as to generally treat diseases linked to the overproduction of IL1β or TNFα as well as acute or chronic inflammatory diseases, rheumatoid arthritis, septic shock, autoimmune diabetes, graft rejection in the host, etc. | 2011-07-28 |
20110182923 | NOVEL GROUP B STREPTOCOCCUS ANTIGENS | 2011-07-28 |
20110182924 | PROTEINS WITH REPETITIVE BACTERIAL-IG-LIKE (BIG) DOMAINS PRESENT IN LEPTOSPIRA SPECIES - The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the | 2011-07-28 |
20110182925 | Ehrlichia canis DIVA (Differentiate Infected from Vaccinated Animals) - The invention provides | 2011-07-28 |
20110182926 | MINIGENE - The present invention provides minigenes suitable as a prophylactic or therapeutic vaccine against conditions such as cancer, infectious diseases or autoimmune diseases, and pharmaceutical compositions comprising the minigene. The minigenes of the present invention comprise (a) a human tissue plasminogen signal peptide; (b) at least one T-cell epitope; and (c) an | 2011-07-28 |
20110182927 | Inhibitors of DNA Immunostimulatory Sequence Activity - The invention consists of oligonucleotides which inhibit the immunostimulatory activity of ISS-ODN (immunostimulatory sequence oligodeoxynucleotides) as well as methods for their identification and use. The oligonucleotides of the invention are useful in controlling therapeutically intended ISS-ODN adjuvant activity as well as undesired ISS-ODN activity exerted by recombinant expression vectors, such as those used for gene therapy and gene immunization. The oligonucleotides of the invention also have anti-inflammatory activity useful in reducing inflammation in response to infection of a host with ISS-ODN containing microbes, in controlling autoimmune disease and in boosting host Th2 type immune responses to an antigen. The invention also encompasses pharmaceutically useful conjugates of the oligonucleotides of the invention (including conjugate partners such as antigens and antibodies). | 2011-07-28 |
20110182928 | VACCINE AGAINST AMYLOID FOLDING INTERMEDIATE - The invention relates to an improved vaccine to treat Alzheimer's disease. | 2011-07-28 |
20110182929 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA - Disclosed are immunogenic conjugates which elicit an immune response to | 2011-07-28 |
20110182930 | LARGE-SCALE PROCESS FOR THE PREPARATION OF THYLAKOIDS - The present invention relates to a process on a large industrial scale for the production of thylakoids, from photosynthetic organisms, such as from green plant leaf material, to be used as ingredients in food, or additions to food, or dietary supplements, or pharmaceuticals for the purpose of preventing overweight, promoting satiety, reducing food intake, reducing bodyweight, reducing blood insulin concentration and reducing blood fats and percentage body fat in humans and animals. | 2011-07-28 |
20110182931 | IMMORTAL AVIAN CELL LINE AND METHODS OF USE - A avian cell line that supports replication of animal or human viruses, which cell line is adapted to animal-product free growth. The cell line is useful for propagating a virus suitable as a live or a killed vaccine and for virus isolation and diagnostic assays. | 2011-07-28 |
20110182932 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 2011-07-28 |
20110182933 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 2011-07-28 |
20110182934 | IMMUNE SYSTEM STIMULATING NUTRITION - Disclosed is a nutritional composition comprising a combination of non-digestible oligosaccharides and a product obtained by incubating an aqueous substrate by bifidobacteria and optionally a product obtained by incubating an aqueous substrate by | 2011-07-28 |
20110182935 | PREVENTION AND TREATMENT OF SUB-CLINICAL PCVD - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs. | 2011-07-28 |
20110182936 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided. | 2011-07-28 |
20110182937 | Dendritic Cell Vaccines - Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-α), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS). | 2011-07-28 |
20110182938 | INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided. | 2011-07-28 |
20110182939 | Vaccine Adjuvants - The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response. | 2011-07-28 |
20110182940 | METHOD FOR PRODUCING PURIFIED INFLUENZA VIRUS ANTIGEN - The present invention aims to provide a method which enables efficient removal of impurities such as the host proteins from an influenza virus culture liquid by a simple operation, allowing separation and purification of an influenza virus antigen. | 2011-07-28 |
20110182941 | Alphavirus and Alphavirus Replicon Particle Formulations and Methods - Disclosed are methods for preparing dried (preferably lyophilized) preparations comprising a population of alphaviruses or alphavirus replicon particles, a sugar or polyol, a surfactant and a salt and preparations made by these methods, both in the dried form but also as liquids prior to drying or after reconstituting dried preparations. These preparations may further comprise a plasticizer and/or a bulking agent. These preparations are readily reconstituted, with little or no loss in infectivity of the viruses or replicon particles. | 2011-07-28 |
20110182942 | MENINGOCOCCAL MULTIVALENT NATIVE OUTER MEMBRANE VESICLE VACCINE, METHODS OF MAKING AND USE THEREOF - The present technology provides vaccine compositions comprising native outer membrane vesicles (NOMVs) from at least one genetically modified strain of | 2011-07-28 |
20110182943 | METHODS OF IMMUNE OR HEMATOLOGICAL ENHANCEMENT, INHIBITING TUMOUR FORMATION OR GROWTH, AND TREATING OR PREVENTING CANCER, CANCER SYMPTOMS, OR THE SYMPTOMS OF CANCER TREATMENTS - The present invention relates to administration of milk fat or a milk fat analogue, optionally with at least one additional therapeutic factor, preferably lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof, to inhibit tumour formation or growth, maintain or improve one or more of the white blood cell count, the red blood cell count, or the myeloid cell count, reduce cachexia, mucositis, and anemia, stimulate the immune system and treat or prevent cancer and the symptoms of cancer and side-effects of cancer therapies. The methods and medicinal uses of the invention may be carried out by employing dietary (as foods or food supplements), nutraceutical or pharmaceutical compositions. Compositions useful in the methods of the invention are also provided. | 2011-07-28 |
20110182944 | Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein - The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts. | 2011-07-28 |